Arbutus Biopharma
ABUS
94 hedge funds and large institutions have $86.5M invested in Arbutus Biopharma in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 8 closing their positions.
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
18% more funds holding
Funds holding: 80 → 94 (+14)
9% more capital invested
Capital invested by funds: $79.4M → $86.5M (+$7.03M)
5% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 22
0.96% more ownership
Funds ownership: 26.25% → 27.21% (+0.96%)
46% less call options, than puts
Call options by funds: $1.89M | Put options by funds: $3.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4M |
| 2 |
Two Sigma Investments
New York
|
+$2.97M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.31M |
| 5 |
Renaissance Technologies
New York
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Think Investments
San Francisco,
California
|
-$7.1M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.85M |
| 3 |
Morgan Stanley
New York
|
-$1.13M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.02M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$788K |
ABUS Hedge Fund Activity: Q1 2021 in Review
94 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2021, worth a combined $86.5M — up 8.9% from $79.4M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ABUS positions and 8 closed out — a net gain of 16 holders — while 23 added to existing stakes and 22 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4M. The largest seller was Think Investments, exiting entirely with an estimated $7.1M sold.
- 94 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2021, up from 80 in Q4 2020.
- Funds reported $86.5M of Arbutus Biopharma stock for Q1 2021, up 8.9% quarter-over-quarter.
- 24 funds opened new Arbutus Biopharma positions in Q1 2021 and 8 closed out, a net change of +16 holders.
- The largest Arbutus Biopharma buyer in Q1 2021 was Point72 Asset Management, an estimated $4M added.
- The largest Arbutus Biopharma seller in Q1 2021 was Think Investments, an estimated $7.1M sold.
Based on aggregated 13F filings for Q1 2021.